Genomic organization and mutation analyses of the DR5/TRAIL receptor 2 gene in colorectal carcinomas.
Article Details
- CitationCopy to clipboard
Arai T, Akiyama Y, Okabe S, Saito K, Iwai T, Yuasa Y
Genomic organization and mutation analyses of the DR5/TRAIL receptor 2 gene in colorectal carcinomas.
Cancer Lett. 1998 Nov 27;133(2):197-204.
- PubMed ID
- 10072170 [ View in PubMed]
- Abstract
The DR5/TRAIL receptor 2 gene is a novel TNF receptor family member and induces apoptosis by overexpression of its product. DR5 is located on chromosome 8p21, where allelic deletions are often observed in advanced colorectal cancers. This evidence led us to examine whether or not mutations of the DR5 gene exist in these tumors. We determined the genomic structure of DR5, which consists of nine exons. DR5 has two alternatively spliced isoforms. All seven colorectal cancer (CRC) cell lines examined expressed the longer isoform predominantly. No somatic mutation was found in 41 CRC cases. Loss of heterozygosity of DR5 was found in nine (52.9%) of the 17 informative cases, which is similar to the previously reported frequencies observed for 8p21-22 in colorectal cancers. These findings suggest that inactivation of the DR5 gene may play only a small role, if any, in colorectal tumorigenesis.